Oral Prostacyclin Pathway Agents Used in PAH: A Targeted Literature Review.

Charles D BurgerYuen TsangMarie ChiversRiya Vijay VekariaGurinderpal DoadNikki AtkinsSumeet Panjabi

Published in: ClinicoEconomics and outcomes research : CEOR (2024)

Given differences in trial- and real-world outcomes, number of prior therapies, and dosing, personalizing the choice of oral PPA is critical to maximizing the benefit for individual patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
clinical trial
peritoneal dialysis
randomized controlled trial
study protocol
pulmonary arterial hypertension
case report
cancer therapy
patient reported outcomes
drug delivery
pulmonary hypertension
phase ii
glycemic control